NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-633-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$50,000.00
Profitability
Miscellaneous
Employees161
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Nantkwest (NASDAQ:NK) Frequently Asked Questions
What is Nantkwest's stock symbol?
Nantkwest trades on the NASDAQ under the ticker symbol "NK."
How were Nantkwest's earnings last quarter?
Nantkwest Inc (NASDAQ:NK) issued its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.06. The biotechnology company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.10 million. Nantkwest had a negative return on equity of 48.18% and a negative net margin of 125,903.34%. View Nantkwest's Earnings History.
When is Nantkwest's next earnings date?
What price target have analysts set for NK?
2 brokers have issued 12-month price objectives for Nantkwest's stock. Their forecasts range from $1.00 to $3.50. On average, they anticipate Nantkwest's stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price. View Analyst Price Targets for Nantkwest.
What is the consensus analysts' recommendation for Nantkwest?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nantkwest.
Has Nantkwest been receiving favorable news coverage?
Media headlines about NK stock have been trending negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nantkwest earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Nantkwest.
Who are some of Nantkwest's key competitors?
Some companies that are related to Nantkwest include Autolus Therapeutics (AUTL), Translate Bio (TBIO), Cellectis (CLLS), Precision BioSciences (DTIL), Solid Biosciences (SLDB), Avrobio (AVRO), Agenus (AGEN), Prevail Therapeutics (PRVL), Tcr2 Therapeutics (TCRR), Adverum Biotechnologies (ADVM), Harpoon Therapeutics (HARP), Replimune Group (REPL), Gritstone Oncology (GRTS), Scholar Rock (SRRK) and BioCryst Pharmaceuticals (BCRX).
What other stocks do shareholders of Nantkwest own?
Who are Nantkwest's key executives?
Nantkwest's management team includes the folowing people:
- Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
- Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
- Mr. Richard J. Tajak, Consultant (Age 66)
- Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
- Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)
When did Nantkwest IPO?
(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.
Who are Nantkwest's major shareholders?
Nantkwest's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.54%), Vanguard Group Inc. (0.99%), BlackRock Inc. (0.37%), Northern Trust Corp (0.28%), Paloma Partners Management Co (0.13%) and Jane Street Group LLC (0.09%). Company insiders that own Nantkwest stock include John C Thomas and Steve Gorlin. View Institutional Ownership Trends for Nantkwest.
Which institutional investors are selling Nantkwest stock?
NK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc. and Northern Trust Corp. Company insiders that have sold Nantkwest company stock in the last year include John C Thomas and Steve Gorlin. View Insider Buying and Selling for Nantkwest.
Which institutional investors are buying Nantkwest stock?
NK stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Paloma Partners Management Co, Jane Street Group LLC, Parametric Portfolio Associates LLC and Morgan Stanley. View Insider Buying and Selling for Nantkwest.
How do I buy shares of Nantkwest?
Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Nantkwest's stock price today?
One share of NK stock can currently be purchased for approximately $1.38.
How big of a company is Nantkwest?
Nantkwest has a market capitalization of $135.67 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,230,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Nantkwest employs 161 workers across the globe.View Additional Information About Nantkwest.
What is Nantkwest's official website?
How can I contact Nantkwest?
Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]
MarketBeat Community Rating for Nantkwest (NASDAQ NK)
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
